Subham Preetam is the Founder & CEO of N BASE. He is a professional biotechnologist in the field of biorobotics, cancer, immunity, biomedical, and nanometerial research. He is dedicated to the advancement of precision medicine and successful preclinical research to enhance the quality of life for individuals. With extensive cross-disciplinary training and experience in translational research, he is currently focused on various research topics, including microrobotics, soft bio-hybrid robots, and quantum nanoparticles for drug delivery. His research aims to improve the life expectancy of sea animals and humans. Furthermore, he is involved in developing a bio-fluidics nanomedicine system that leverages the latest drug delivery technologies to create personalized solutions for brain cancer patients in South Korea and Sweden. Additionally, he collaborates with researchers from India, Taiwan, Israel, US, Denmark, Singapore, Spain, Portugal, and the United Kingdom on various collaborative projects.

Matrix Pathobiology, Extracellular Matrix, Matrix-mediated cell regulation and singaling, Pharmacological targeting, Biochemical Assays, Proteoglycans, Glycosaminoglycans, Metalloproteinases

Our lab uses genetically modified mouse models and a combination of cell biology, molecular biology, and biochemistry techniques to study the role of altered mitochondrial dysfunction and metabolism in human diseases. A primary analytical tool of the group is metabolomics, which enables the parallel quantification of hundreds of small molecule metabolites. The team also uses computational approaches to integrate datasets from multi-dimensional analyses, including metabolomics, proteomics, and transcriptomics, with the aim to model aging-related disorders and to generate mechanistic hypotheses that will be cross validated experimentally.

Dr. Isabel Varela-Nieto graduated and earned her doctorate in Chemistry, Biochemistry Section, at the University Complutense of Madrid (Spain). She has been a visiting guest scientist at the Medical Schools of Uppsala (FEBS Fellow, Sweden) and San Diego (MEC Sabbatical, USA). She is Professor of Research at the CSIC and group leader at the CIBER of rare diseases (CIBERER, ISCIII) in Madrid. From the early 1990s she has been studying hearing neurobiology and IGF-1 actions. She was the first Chair of the SEBBM Science for Society working group with which she actively collaborates, and member of the FEBS Network working group. She is currently the president of the SEBBM, a member of the FEBS Science and Society Committee and of the ISC Finances Committee.